

Appl. No. 10/091,300  
Amdt. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 1:245/46211

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (previously presented): A method of inhibiting tumor growth comprising administering to a human a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist and a therapeutically effective amount of an epidermal growth factor receptor (EGFR) antagonist.

Claim 2 (previously presented): The method of claim 1, wherein the tumor overexpresses VEGFR.

Claim 3 (previously presented): The method of claim 1, wherein the tumor is a tumor of the colon.

Claim 4 (previously presented): The method of claim 1, wherein the tumor is a non-small cell lung carcinoma (NSCLC).

Claim 5 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist is administered intravenously.

Claim 6 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist is administered orally.

Claim 7 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist inhibits binding of VEGFR to its ligand.

Claim 8 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist binds VEGFR.

Appl. No. 10/091,300  
Amdt. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 1: 245/46211

Claim 9 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist is an antagonist of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

Claim 10 (previously presented): The method of claim 1, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Claim 11 (previously presented): The method of claim 10, wherein the antibody comprises a constant region of a human antibody.

Claim 12 (previously presented): The method of claim 11, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

*a*  
Claim 13 (previously presented): The method of claim 11, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 14 (previously presented): The method of claim 11, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Claim 15 (withdrawn): The method of claim 1, wherein the VEGF receptor antagonist comprises a small molecule specific for VEGFR.

Claim 16 (previously presented): The method of claim 1, wherein the tumor overexpresses EGFR.

Claim 17 (previously presented): The method of claim 1, wherein the EGFR antagonist is administered intravenously.

Claim 18 (previously presented): The method of claim 1, wherein the EGFR antagonist is administered orally.

Appl. No. 10/091,300  
Amtd. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 1:245/46211

Claim 19 (previously presented): The method of claim 1, wherein the EGFR antagonist inhibits binding of EGFR to its ligand.

Claim 20 (previously presented): The method of claim 1, wherein the EGFR antagonist binds EGFR.

Claim 21 (previously presented): The method of claim 1, wherein the EGFR antagonist inhibits binding of EGFR to ATP.

Claim 22 (previously presented): The method of claim 1, wherein the EGFR antagonist comprises an antibody, or functional equivalent thereof, specific for EGFR.

Claim 23 (previously presented): The method of claim 22, wherein the antibody comprises a constant region of a human antibody.

Claim 24 (previously presented): The method of claim 23, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 25 (previously presented): The method of claim 22, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 26 (previously presented): The method of claim 22, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Claim 27 (withdrawn): The method of claim 1, wherein the EGFR antagonist comprises a small molecule specific for EGFR.

Claim 28 (previously presented): The method of claim 1, wherein the method further comprises administering a chemotherapeutic agent or radiation.

Appl. No. 10/091,300  
Amdt. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 1:245/46211

Claim 29 (withdrawn): A method of inhibiting tumor growth comprising administering to a human a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist and radiation.

Claim 30 (withdrawn): The method of claim 29, wherein the tumor overexpresses VEGFR.

Claim 31 (withdrawn): The method of claim 29, wherein the tumor is a tumor of the colon.

Claim 32 (withdrawn): The method of claim 29, wherein the tumor is a non small cell lung carcinoma (NSCLC).

Claim 33 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist is administered intravenously.

Claim 34 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist is administered orally.

Claim 35 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist inhibits binding of VEGFR to its ligand.

Claim 36 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist binds VEGFR.

Claim 37 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist is an antagonist of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

Claim 38 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Appl. No. 10/091,300  
Amdt. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 11245/46211


Claim 39 (withdrawn): The method of claim 38, wherein the antibody comprises a constant region of a human antibody.

Claim 40 (withdrawn): The method of claim 39, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 41 (withdrawn): The method of claim 39, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 42 (withdrawn): The method of claim 39, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Claim 43 (withdrawn): The method of claim 29, wherein the VEGF receptor antagonist comprises a small molecule specific for VEGFR.

 Claim 44 (withdrawn): The method of claim 29, wherein the method further comprises administering radiation.

Claim 45 (withdrawn): A method of inhibiting tumor growth comprising administering to a human a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist and a chemotherapeutic agent.

Claim 46 (withdrawn): The method of claim 45, wherein the tumor overexpresses VEGFR.

Claim 47 (withdrawn): The method of claim 45, wherein the tumor is a tumor of the colon.

Claim 48 (withdrawn): The method of claim 45, wherein the tumor is a non-small cell lung carcinoma (NSCLC).

Appl. No. 10/091,300  
Amdt. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 11245/46211

Claim 49 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist is administered intravenously.

Claim 50 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist is administered orally.

Claim 51 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist inhibits binding of VEGFR to its ligand.

Claim 52 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist binds VEGFR.

Claim 53 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist is an antagonist of *fms*-like tyrosine kinase receptor (flt-1) VEGFR-1.

Claim 54 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Claim 55 (withdrawn): The method of claim 45, wherein the antibody comprises a constant region of a human antibody.

Claim 56 (withdrawn): The method of claim 55, wherein the antibody is a chimeric antibody comprising a variable region of a mouse antibody.

Claim 57 (withdrawn): The method of claim 55, wherein the antibody is a humanized antibody comprising a variable region having complementarity-determining regions (CDRs) of a mouse antibody and framework regions of a human antibody.

Claim 58 (withdrawn): The method of claim 55, wherein the antibody is a human antibody comprising a variable region of a human antibody.

Appl. No. 10/091,300  
Amdt. dated Sept. 25, 2003  
Reply to Office Action dated Aug. 25, 2003

Docket No. 1:245/46211

Claim 59 (withdrawn): The method of claim 45, wherein the VEGF receptor antagonist comprises a small molecule specific for VEGFR.

Claim 60 (withdrawn): The method of claim 45, wherein the chemotherapeutic agent is not conjugated to the VEGF receptor antagonist.

Claim 61 (withdrawn): The method of claim 45, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, doxorubicin, taxol and combinations thereof.

Claim 62 (previously presented): A kit for inhibiting tumor growth comprising a therapeutically effective amount of an epidermal growth factor receptor (EGFR) antagonist and a therapeutically effective amount of a vascular endothelial growth factor (VEGF) receptor antagonist.

Claim 63 (previously presented): The kit of claim 62, wherein the EGFR antagonist comprises an antibody, or functional equivalent thereof, specific for EGFR.

Claim 64 (withdrawn): The kit of claim 62, wherein the EGFR antagonist comprises a small molecule specific for EGFR.

Claim 65 (previously presented): The kit of claim 62, wherein the VEGFR antagonist comprises an antibody, or functional equivalent thereof, specific for VEGFR.

Claim 66 (withdrawn): The kit of claim 62, wherein the VEGFR antagonist comprises a small molecule specific for VEGFR.

Claim 67 (previously presented): The kit of claim 62, wherein the kit further comprises a chemotherapeutic agent or radiation.